M endelian susceptibility to mycobacterial infection (MIM 209950) is a rare and heterogeneous syndrome. [1] [2] [3] Affected individuals develop severe clinical disease caused by weakly virulent mycobacterial species, such as bacille Calmette-Guérin (BCG) vaccines and environmental nontuberculous mycobacteria (NTM). The clinical phenotype ranges from fatal disseminated infection in early childhood to focal recurrent infection in adults. In the last 5 years, considerable genetic heterogeneity has been documented. Mutations have been found in 4 genes: IFNGR1, encoding the interferon gamma (IFN␥) receptor ligand-binding chain; IFNGR2, encoding the IFN␥ receptor signal-transducing chain; IL12B, encoding the p40 subunit of interleukin (IL)-12; and IL12RB1 encoding the IL-12 receptor ␤1 chain. Different types of mutations define 8 inherited disorders: complete recessive IFN␥R1 deficiency with 4 -6 or without 7 receptor surface expression; partial, as opposed to complete, IFN␥R1 deficiency with recessive 8 or dominant inheritance 9 ; recessive complete 10 or partial 11 IFN␥R2 deficiency; complete recessive IL-12p40 12 ; and IL-12R␤1 deficiency. 13, 14 However, a molecular etiology is still lacking for a majority of the patients. Complete IFN␥R1 [1] [2] [3] [4] [5] [6] [7] and IFN␥R2 8 deficiency are responsible for early-onset overwhelming mycobacterial disease. Partial IFN␥R1 defects 8, 9 and partial IFN␥R2 deficiency, 11 like complete IL-12p40 12 and IL-12R␤1 deficiency, 13, 14 are responsible for milder clinical forms. [1] [2] [3] The diversity of the genes and pathogenic mutations involved renders molecular diagnosis challenging. For example, complete IFN␥R1 deficiency may be caused by mutations preventing expression of the receptor 4 -6 or binding of the surface receptor to IFN␥. 7 Moreover, cells with complete IFN␥R deficiency do not respond to IFN␥, 4 -7 whereas cells with partial IFN␥R deficiency respond to IFN␥ at high concentration. 8, 9, 11 Finally, most patients display low levels of IFN␥ production by peripheral blood cells. 1,2 Cumbersome diagnostic investigations combining highly specialized functional, biochemical, and genetic assays are, therefore, required in most patients with the syndrome. An accurate and rapid molecular diagnosis is, however, essential for the rational and efficient treatment of the patient. Indeed, children with complete IFN␥R deficiency do not achieve sustained remission with antibiotics alone and do not respond to exogenous IFN␥, resulting from a lack of functional receptors. The outcome seems to be often fatal and bone marrow transplantation should be considered. [1] [2] [3] 15 In contrast, the administration of subcutaneous IFN␥ together with antibiotics is often beneficial in patients with other genetic defects, and full remission of mycobacterial disease has been achieved. [1] [2] [3] The lack of a simple method for rapidly discriminating between patients with complete IFN␥R deficiency and patients with other genetic etiologies greatly compromises the management of these patients.
We measured IFN␥ by enzyme-linked immunosorbent assay (ELISA) in the plasma of healthy individuals and patients with various forms of Mendelian susceptibility to mycobacterial infection. IFN␥ is undetectable (Ͻ5 pg/mL) in the serum and plasma of 6 healthy individuals tested (not shown). All patients had suffered from BCG and/or NTM clinical disease when the blood sample was taken. Patients with IL-12p40 (n ϭ 3) and with IL-12-receptor ␤1 chain deficiency (n ϭ 5)-like patients with partial dominant IFN␥R1 deficiency (n ϭ 7) and partial re-cessive IFN␥R2 deficiency (n ϭ 1)-had no detectable IFN␥ in the plasma (Fig 1) . We found low levels of IFN␥ (median ϭ 57 Ϯ 9.9 pg/mL) in the plasma of patients with partial recessive IFN␥R1 deficiency (n ϭ 2). Remarkably, we found very high levels of IFN␥ in the plasma of patients with complete IFN␥R1 deficiency (n ϭ 5; median ϭ 252 Ϯ 113 pg/mL) and complete IFN␥R2 deficiency (n ϭ 2; median ϭ 433 Ϯ 306 pg/mL). To validate these results, we measured IFN␥ in the serum of 40 other children with unexplained BCG and/or NTM clinical disease. High levels of IFN␥ were found in 1 child, who was subsequently diagnosed with complete IFN␥R1 deficiency (n ϭ 6; median 249 Ϯ 101 pg/mL). Complete IFN␥R deficiency was functionally and genetically excluded in the remaining 39 patients.
These results may reflect the more severe course of mycobacterial disease in patients with complete IFN␥R deficiency, resulting in more intense and sustained IFN␥ secretion. However, high plasma levels of IFN␥ (35 pg/mL) in 1 asymptomatic child with a family history, diagnosed at birth suggests that it is not the case (not shown). Paradoxically, patients with complete IFN␥R deficiency have previously been shown to have impaired secretion of IFN␥, attributable to a secondary defect in IL-12 production. 6 As IFN␥R is ubiquitously expressed in the organism, our results suggest that patients with complete IFN␥R deficiency cannot eliminate blood IFN␥, resulting from a lack of binding (IFN␥R1 deficiency) or a lack of internalization (IFN␥R2 deficiency) of the cytokine. This would also account for the detectable levels of IFN␥ in the plasma of patients with partial recessive IFN␥R1 deficiency, in whom the receptor mutation probably reduces but does not abolish the affinity of the receptor for IFN␥. 8 Receptors from patients with dominant IFN␥R1 deficiency probably bind and/or recycle sufficient amounts of IFN␥ to keep serum levels undetectable. Profound defects of IFN␥ production (IL-12p40 and IL-12R␤1 deficiencies) in patients with functional IFN␥ receptors are not associated with high levels of IFN␥ in the plasma.
In any event, plasma IFN␥ determination by ELISA is a simple, cheap, rapid, and efficient way to guide molecular diagnosis and to provide a rational basis for the treatment of patients with Mendelian susceptibility to mycobacterial infection. High levels (our threshold of 80 pg/mL is Ͼ2 standard deviations above the mean level in patients with partial recessive IFN␥R1 defects) of IFN␥ in the serum of a patient with BCG and/or NTM clinical disease should lead to the consideration of bone marrow transplantation options while searching for and validating null mutations of IFNGR1 or IFNGR2. Undetectable or low levels of IFN␥ should lead to the child being treated with subcutaneous IFN␥ while searching for mild mutations of IFNGR1 and IFNGR2, or null mutations of IL12B and IL12RB1 . Fig 1. Serum levels of IFN␥ in patients with known genetic etiologies for Mendelian susceptibility to mycobacterial infection. Known genetic etiologies include complete recessive IFN␥R1 deficiency (CR1), complete recessive IFN␥R2 deficiency (CR2), and partial recessive IFN␥R1 deficiency (PR1). Other cases (others) include partial dominant IFN␥R1 deficiency (n ϭ 7), partial recessive IFN␥R2 deficiency (n ϭ 1), complete IL-12p40 deficiency (n ϭ 3), and complete IL-12R␤1 deficiency (n ϭ 5). The experiment was performed in a single laboratory using the IFN␥ ELISA kit: PeliKine Compact, Human IFN␥ ELISA kit (CLB, The Netherlands). Its sensitivity is 5 pg/mL and the linear range is 5 pg/mL to 500 pg/mL. Our study was performed in compliance with institutional requirements and an informed consent was obtained from each patient's family.
